Is Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?

Simply Wall St.

Yesterday

If you are wondering whether Ultragenyx Pharmaceutical at around US$20.52 is starting to look mispriced, you are not alone. This article will walk through what that number might really mean for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611174552"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611174552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611174552?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-16 07:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611174552","market":"us","top_or_hot":-1,"title":"Is Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Ultragenyx Pharmaceutical at around US$20.52 is starting to look mispriced, you are not alone. This article will walk through what that number might really mean for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-mispriced-after-steep-mult\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-16 07:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-mispriced-after-steep-mult><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Ultragenyx Pharmaceutical at around US$20.52 is starting to look mispriced, you are not alone. This article will walk through what that number might really mean for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-mispriced-after-steep-mult\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-mispriced-after-steep-mult","article_id":"2611174552","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/is-ultragenyx-pharmaceutical-rare-mispriced-after-steep-mult","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611174552","pubTimestamp":1771197463,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Ultragenyx Pharmaceutical at around US$20.52 is starting to look mispriced, you are not alone. This article will walk through what that number might really mean for valuation.\nThe stock has seen sharp moves recently, with a 16.9% decline over the last 7 days, an 8.8% decline over 30 days, a 13.1% decline year to date, and a 51.7% decline over the past year, on top of a 57.9% decline over 3 years and an 86.1% decline over 5 years.\nRecent news coverage around...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RARE":"Ultragenyx Pharmaceutical Inc","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Ultragenyx Pharmaceutical（罕见）在股价多年大幅下跌后是否定价错误？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":1.5,"DCF":1},"content_text":"If you are wondering whether Ultragenyx Pharmaceutical at around US$20.52 is starting to look mispriced, you are not alone. This article will walk through what that number might really mean for valuation. The stock has seen sharp moves recently, with a 16.9% decline over the last 7 days, an 8.8% decline over 30 days, a 13.1% decline year to date, and a 51.7% decline over the past year, on top of a 57.9% decline over 3 years and an 86.1% decline over 5 years. Recent news coverage around Ultragenyx has focused on its rare disease drug pipeline and funding needs, which helps explain why sentiment and risk perception can shift quickly. For a company like this, headlines around clinical progress, regulatory updates, partnerships or capital raising can all feed directly into how investors think about what the shares are worth. On our valuation checklist, Ultragenyx scores 4 out of 6, suggesting it screens as undervalued on four of the six metrics we look at. You can see the full breakdown in our valuation score of 4. Next, we will look at what each valuation method is telling you, and then finish with a way to tie those numbers together into a more complete view.  Find out why Ultragenyx Pharmaceutical's -51.7% return over the last year is lagging behind its peers. AdvertisementApproach 1: Ultragenyx Pharmaceutical Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes projected future cash flows and then discounts them back to today to estimate what the entire business could be worth right now. For Ultragenyx Pharmaceutical, the latest twelve month free cash flow is a loss of $488.7 million, so the model relies heavily on future estimates. Analysts and extrapolated data point to free cash flow turning positive in the coming years and reaching $938 million in 2030, with a 2 Stage Free Cash Flow to Equity approach used to extend those projections further out. Using these cash flow projections, Simply Wall St estimates an intrinsic value of about $278.37 per share. Compared with the recent share price of about $20.52, the model implies the stock trades at a 92.6% discount to this estimate, which flags Ultragenyx as materially undervalued under these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Ultragenyx Pharmaceutical is undervalued by 92.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. RARE Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ultragenyx Pharmaceutical. Approach 2: Ultragenyx Pharmaceutical Price vs Sales For companies that are not yet profitable, the P/S ratio is often more useful than P/E because it focuses on revenue rather than earnings, which can still be negative during heavy investment phases. What investors are really weighing here is how much they are paying for each dollar of sales, given the company’s growth potential and risk profile. Higher expected growth or lower perceived risk can justify a higher P/S, while slower expected growth or higher risk typically points to a lower, more cautious multiple. Ultragenyx currently trades on a P/S of 2.94x, compared with the Biotechs industry average of 11.28x and a peer average of 6.39x. Simply Wall St also calculates a proprietary Fair Ratio of 2.32x for Ultragenyx, which is the P/S level it would expect based on factors such as earnings growth, industry, profit margins, market cap and company specific risks. This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for those company specific characteristics rather than assuming all biotechs deserve the same multiple. With the current 2.94x P/S sitting above the 2.32x Fair Ratio, the stock screens as overvalued on this metric. Result: OVERVALUED NasdaqGS:RARE P/S Ratio as at Feb 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies. Upgrade Your Decision Making: Choose your Ultragenyx Pharmaceutical Narrative Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Ultragenyx Pharmaceutical into a simple story that links assumptions about future revenue, earnings and margins to a financial forecast, a fair value, and then a clear comparison with today’s price. All of this is available in an easy tool on the Community page that updates as new news or earnings arrive and can reflect very different views. For example, there is a bullish Ultragenyx Narrative built around a fair value near US$120.29 and stronger growth assumptions, versus a cautious Narrative closer to US$35.00 that stresses pipeline, pricing and execution risks. This gives you a structured way to decide how the current share price around US$20.52 lines up with the story you find more convincing. Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying! NasdaqGS:RARE 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}